The loss of neocortical P2Y(2) nucleotide receptors is associated with Alzheimer's disease neuropathology

The loss of neocortical P2Y(2) nucleotide receptors is associated with Alzheimer's disease neuropathology

Bibliographic Details
Main Authors:	Lai, M, Tan, M, Kirvell, S, Esiri, M, Chen, C, Francis, P
Format:	Conference item
Published:	2008

Similar Items

Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology.
by: Lai, M, et al.
Published: (2008)

Differential alterations of neocortical GluN receptor subunits in patients with mixed subcortical ischemic vascular dementia and Alzheimer's disease.
by: Mohamed, N, et al.
Published: (2015)

Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.
by: Tsang, S, et al.
Published: (2006)

5-HTTPR is associated with altered neocortical [H-3]citalopram binding and anxiety in Alzheimer disease
by: Tsang, S, et al.
Published: (2003)

Loss of serotonin 5-HT2A receptors in, the temporal cortex correlates with cognitive decline in Alzheimer's disease
by: Lai, K, et al.
Published: (2004)

Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.
by: Wegner, C, et al.
Published: (2006)

Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.
by: Lai, M, et al.
Published: (2005)

Neuropathology of Alzheimer's Disease
by: Gomez-Isla, T, et al.
Published: (2008)

Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis.
by: Tsang, S, et al.
Published: (2008)

The neuropathological diagnosis of Alzheimer’s disease
by: Michael A. DeTure, et al.
Published: (2019-08-01)

Lewy Body Variant of Alzheimer's Disease: Selective Neocortical Loss of t-SNARE Proteins and Loss of MAP2 and α-Synuclein in Medial Temporal Lobe
by: Elizabeta B. Mukaetova-Ladinska, et al.
Published: (2009-01-01)

Illustrated Neuropathologic Diagnosis of Alzheimer’s Disease
by: Nicholas Doher, et al.
Published: (2023-07-01)

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
by: Kolstoe, SE, et al.
Published: (2009)

Pro: Can neuropathology really confirm the exact diagnosis?
by: Esiri, M
Published: (2010)

Evidence of Filamin A loss of solubility at the prodromal stage of neuropathologically-defined Alzheimer’s disease
by: Etienne Aumont, et al.
Published: (2022-11-01)

Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex.
by: Lai, M, et al.
Published: (2001)

Comorbid neuropathology and atypical presentation of Alzheimer's disease
by: Stefanie D. Pina‐Escudero, et al.
Published: (2024-07-01)

Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease
by: Helena Colvee-Martin, et al.
Published: (2024-03-01)

Cognitive resilience and severe Alzheimer’s disease neuropathology
by: Narges Ahangari, et al.
Published: (2023-01-01)

Alzheimer disease neuropathology:understanding autonomic dysfunction
by: Eliasz Engelhardt, et al.

Neuropathological Mechanisms Associated with Pesticides in Alzheimer’s Disease
by: Bor Luen Tang
Published: (2020-03-01)

Neuropathological assessment of the lesions of significance in vascular dementia.
by: Esiri, M, et al.
Published: (1997)

NEUROPATHOLOGICAL CHANGES IN THE PDAPP TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE
by: P. Pasbakhsh, et al.
Published: (2005-06-01)

NEUROPATHOLOGICAL CHANGES IN THE PDAPP TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE
by: P. Pasbakhsh, et al.
Published: (2005-06-01)

Alzheimer’s disease neuropathological change and loss of matrix/neuropil in patients with idiopathic Normal Pressure Hydrocephalus, a model of Alzheimer’s disease
by: Sylwia Libard, et al.
Published: (2019-05-01)

Serotonin 5-HT2A receptor alterations in the postmortem neocortex of behaviorally assessed Alzheimer patients
by: Lai, M, et al.
Published: (2003)

Transcriptional alterations related to neuropathology and clinical manifestation of Alzheimer's disease.
by: Aderbal R T Silva, et al.
Published: (2012-01-01)

Genome-wide profiling of alternative splicing in Alzheimer's disease
by: Lai, M, et al.
Published: (2014)

Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer’s disease
by: Emilie T. Reas, et al.
Published: (2017-08-01)

Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex
by: Lee, J, et al.
Published: (2010)

Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex.
by: Lee, J, et al.
Published: (2010)

Longitudinal cognitive performance of Alzheimer's disease neuropathological subtypes
by: Madeline Uretsky, et al.
Published: (2021-01-01)

Association between subcortical vascular disease on CT and neuropathological findings.
by: Rossi, R, et al.
Published: (2004)

Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.
by: Lai, M, et al.
Published: (2011)

The neurochemistry of serotonin (5-HT) in Alzheimer's disease and BPSD
by: Chen, C, et al.
Published: (2003)

Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
by: Jaime Silva, et al.
Published: (2022-05-01)

Salidroside reduces neuropathology in Alzheimer’s disease models by targeting NRF2/SIRT3 pathway
by: Yuyuan Yao, et al.
Published: (2022-11-01)

Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease.
by: Lai, M, et al.
Published: (2003)

Epigenetic Modifications in Alzheimer’s Neuropathology and Therapeutics
by: Michelle Esposito, et al.
Published: (2019-05-01)

Upregulation of AMPA receptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease.
by: Mohamed, N, et al.
Published: (2011)